Details

Autor(en) / Beteiligte

• Maeda, Yuichi
• Hirano, Toru
• Ebina, Kosuke
• Hara, Ryota
• Hashimoto, Motomu
• Yamamoto, Wataru
• Murakami, Kosaku
• Kotani, Takuya
• Hata, Kenichiro
• Son, Yonsu
• Amuro, Hideki
• Onishi, Akira
• Jinno, Sadao
• Katayama, Masaki
• Kumanogoh, Atsushi

Titel

Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study

Ist Teil von

• Rheumatology international, 2021-07, Vol.41 (7), p.1233-1241

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2021

Quelle

SpringerLink

Beschreibungen/Notizen

• Objective We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement. Methods We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement. We investigated the clinical disease activity index (CDAI) at baseline and 12 weeks after the initiation of bDMARDs. We compared the improvement of the markers between aIL-6 and other bDMARDs. Results Treatment with aIL-6 significantly increased ΔCDAI ( n  = 91, 15.4 ± 1.1; mean ± SEM) in patients with knee joint involvement, compared to other bDMARDs ( n  = 232, 11.0 ± 0.7) at 12 weeks ( P  = 0.006). Following the multivariate analysis adjusted by the CDAI levels at baseline, age, gender, concomitant use of methotrexate, and the first use of bDMARDs, ΔCDAI levels were significantly higher in aIL-6, compared to other bDMARDs ( P  = 0.02). However, there was no significant difference in ΔCDAI improvement between aIL-6 ( n  = 162, 5.9 ± 0.6) and other bDMARDs ( n  = 573, 6.2 ± 0.4) in patients without swollen knee joints. ΔCDAI levels were equally increased in patients with shoulder and elbow joint involvement. Conclusion aIL-6 was more effective in the patients with RA and knee joint involvement, compared to other bDMARDs.